<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53630">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408003</url>
  </required_header>
  <id_info>
    <org_study_id>MFredholm</org_study_id>
    <nct_id>NCT02408003</nct_id>
  </id_info>
  <brief_title>Comparing the Effects on Cardiac Function of Levosimendan Versus Milrinone.</brief_title>
  <official_title>Comparing the Lusitropic Effect of Levosimendan and Milrinone Using Strain Analysis in Patients Undergoing Open Aortic Valve Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to compare the effects of two drugs, levosimendan and milrinone, on
      cardiac muscle, both in terms of contractility and relaxation. Half of the participants will
      be randomized to each drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic stenosis is associated with myocardial hypertrophy and diastolic dysfunction. In
      patients undergoing open aortic valve replacement surgery due to stenosis, the investigators
      want to compare the effect on myocardial relaxation between two commonly used drugs,
      levosimendan and milrinone, using catheter-based measurements in combination with
      echocardiographic evaluation.

      Standard anaesthesia and surgical care for these patients is performed. After surgery is
      completed and the participant is transferred to the intensive care unit, the studies are
      performed during general anaesthesia and the participants still connected to a respirator
      with controlled ventilation.

      Echocardiographic data will be collected simultaneously with hemodynamic parameters - first
      at two control measurements, then after each of two different doses of the drug. Preload,
      afterload and heart rate will be kept stable during the experiment. The echocardiographic
      data is later analyzed offline for strain and strain rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in diastolic strain rate</measure>
    <time_frame>30 and 60 min after start of iv infusion</time_frame>
    <description>Diastolic strain rate defined as peak E wave strain rate as measured by 2D speckle tracking of the left ventricular wall.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in systolic strain and strain rate</measure>
    <time_frame>30 and 60 min after start of iv infusion</time_frame>
    <description>Systolic strain and strain rate defined as their respective peak values during systole, measured by 2D speckle tracking of the left ventricular wall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac output</measure>
    <time_frame>30 and 60 min after start of iv infusion</time_frame>
    <description>Measured through pulmonary artery thermodilution as liters per minute. A baseline measurement is done before infusion is started.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min.
nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milrinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min.
nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Data is collected before intervention as two controls, then after a first (half) dose, and finally after a second (full) dose.</description>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Daxim</other_name>
    <other_name>Simdax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>Data is collected before intervention as two controls, then after a first (half) dose, and finally after a second (full) dose.</description>
    <arm_group_label>Milrinone</arm_group_label>
    <other_name>Primacor</other_name>
    <other_name>Corotrop</other_name>
    <other_name>Milicor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has aortic valve stenosis

          -  Subject is scheduled for open heart aortic valve replacement with or without
             simultaneous coronary artery bypass grafting

        Exclusion Criteria:

          -  Less than normal systolic function, defined as ejection fraction less than 0,5

          -  Non-sinus rhythm

          -  Any major surgical complication

          -  Problems understanding the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Anesthesia and Intensive Care, University of Gothenburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Fredholm, MD</last_name>
    <phone>+46313427448</phone>
    <email>martin.fredholm@gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven-Erik Ricksten</last_name>
    <phone>+46313427433</phone>
    <email>sven-erik.ricksten@aniv.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thoraxoperation/TIVA, Sahlgrenska universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 20, 2015</lastchanged_date>
  <firstreceived_date>March 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Martin Fredholm</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Transesophageal</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Milrinone</keyword>
  <keyword>Levosimendan</keyword>
  <keyword>Strain</keyword>
  <keyword>Deformation</keyword>
  <keyword>Diastole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simendan</mesh_term>
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
